RECRUITINGINTERVENTIONAL
Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation
Resilience to Antibiotic-induced Obesogenic Microbiota Vertically Transferred to the Neonatal Gut: Discovering Mechanism of Microbiota Modulation
About This Trial
The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.
Who May Be Eligible (Plain English)
Who May Qualify:
Pregnant women (n=125) and their newborn children who receive antibiotic treatment at delivery.
Who Should NOT Join This Trial:
- Chorioamnionitis
- Pre-eclampsia and hepatogestosis
- Suspected malformation or serious condition of the foetus and neonates
- Serious infection or other conditions not permitting breast milk feeding
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Pregnant women (n=125) and their newborn children who receive antibiotic treatment at delivery.
Exclusion Criteria:
* Chorioamnionitis
* Pre-eclampsia and hepatogestosis
* Suspected malformation or serious condition of the foetus and neonates
* Serious infection or other conditions not permitting breast milk feeding
Treatments Being Tested
DIETARY_SUPPLEMENT
Synbiotic Supplement
Bifidobacterium bifidum and human milk oligosaccharides (HMOs)
OTHER
Placebo
Maltodextrin
Locations (1)
Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku
Turku, Valitse Maakunta., Finland